Therapeutic Action
Antiretroviral, HIV nucleotide reverse transcriptase inhibitor
PDF page 307
Loading InternPractice…
Drug reference
Antiretroviral, HIV nucleotide reverse transcriptase inhibitor
PDF page 307
HIV infection with or without chronic hepatitis B coinfection, in combination with other antiretrovirals Chronic hepatitis B without HIV coinfection, in monotherapy
PDF page 307
Administer with caution and monitor use in patients with renal impairment, osteoporosis. In the event of deterioration of renal function, switch to another antiretroviral. Avoid combination (or monitor renal function in the event of combination) with nephrotoxic drugs: aminoglycosides (e.g. gentamicin, streptomycin), amphotericin B, pentamidine, NSAIDs, etc. May cause: gastrointestinal disturbances (nausea, vomiting, diarrhoea, etc.), dizziness, fatigue, skin rash; renal impairment, bone loss (osteoporosis, fractures), pancreatitis. Pregnancy: no contra-indication
PDF page 307
300 mg tablet, equivalent to 245 mg of tenofovir disoproxil
PDF page 307
Child 35 kg and over and adult: 300 mg once daily
PDF page 307
Depending on the efficacy and tolerance of tenofovir.
PDF page 307
Tenofovir is also used for HIV pre-exposure and post-exposure prophylaxis, in combination with other antiretrovirals. Also comes in fixed-dose combinations containing tenofovir and other antiretrovirals for the treatment of HIV infection. Preferably use these formulations when available.
PDF pages 307, 308
– – Below 25 °C
PDF page 308
300 mg once daily
PDF page 307